Sotera Health (NASDAQ:SHC) Posts Earnings Results, Misses Estimates By $0.01 EPS

Sotera Health (NASDAQ:SHC) posted its quarterly earnings results on Tuesday. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01), Briefing.com reports. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The company had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. During the same period last year, the company earned $0.18 earnings per share. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. Sotera Health updated its FY 2024 guidance to 0.670-0.750 EPS and its FY24 guidance to $0.67-0.75 EPS.

Sotera Health Stock Performance

Shares of SHC stock traded up $0.39 during trading on Wednesday, reaching $15.81. The company had a trading volume of 884,591 shares, compared to its average volume of 1,304,161. The firm’s 50 day simple moving average is $15.94 and its two-hundred day simple moving average is $13.67. Sotera Health has a one year low of $10.71 and a one year high of $17.44. The company has a debt-to-equity ratio of 5.46, a current ratio of 2.93 and a quick ratio of 2.59. The company has a market capitalization of $4.48 billion, a PE ratio of 112.93 and a beta of 2.08.

Insiders Place Their Bets

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 55.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Citigroup lifted their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Finally, Barclays boosted their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.